Pharsight

Sympazan patents expiration

SYMPAZAN's oppositions filed in EPO
SYMPAZAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765167 AQUESTIVE Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2024

(4 months from now)

US8603514 AQUESTIVE Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(6 months from now)

Sympazan is owned by Aquestive.

Sympazan contains Clobazam.

Sympazan has a total of 2 drug patents out of which 0 drug patents have expired.

Sympazan was authorised for market use on 01 November, 2018.

Sympazan is available in film;oral dosage forms.

The generics of Sympazan are possible to be released after 03 April, 2024.

Drugs and Companies using CLOBAZAM ingredient

Market Authorisation Date: 01 November, 2018

Treatment: NA

Dosage: FILM;ORAL

More Information on Dosage

SYMPAZAN family patents

Family Patents
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11541002 OTTER PHARMS NA
Jan, 2040

(16 years from now)

Sympazan is owned by Otter Pharms.

Sympazan contains Clobazam.

Sympazan has a total of 1 drug patent out of which 0 drug patents have expired.

Sympazan was authorised for market use on 01 November, 2018.

Sympazan is available in film;oral dosage forms.

Sympazan can be used as method of treating seizures.

The generics of Sympazan are possible to be released after 31 January, 2040.

Drugs and Companies using CLOBAZAM ingredient

Market Authorisation Date: 01 November, 2018

Treatment: Method of treating seizures

Dosage: FILM;ORAL

More Information on Dosage

SYMPAZAN family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic